logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
NRx Pharmaceuticals, Inc.
(NRXP)
ZYESAMI
Results of a review conducted by DSMB in patients with critical COVID-19 respiratory failure who were enrolled in the ACTIV-3b (TESICO) study of ZYESAMI were reported on May 25, 2022. The DSMB recommended stopping further randomization to ZYESAMI due to ZYESAMI not meeting the futility guidelines outlined by the pre-approved analytical plan.
-
-
05/26/2022
AIM ImmunoTech Inc.
(AIM)
Ampligen
After at least 12 weeks of Ampligen treatment, four patients with new onset Myalgic encephalomyelitis/chronic fatigue syndrome, following acute COVID-19, experienced a reduction in fatigue- reported on May 18, 2022.
An IND application to be submitted with the FDA for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions
-
05/19/2022
SIMCERE PHARMA
SIM0417 to treat Covid-19
Clinical trial approval from National Medical Products Administration in China was received for SIM0417 for the treatment of Covid-19-reported on May 17, 2022.
-
-
05/18/2022
Synairgen plc
(SNG.L)
SNG001
Phase 3 SPRINTER study of SNG001 did not meet the primary endpoints of discharge from hospital and recovery- reported on 21 February 2022.
-
-
05/17/2022
Akston Biosciences Corporation
AKS-452- COVID-19 vaccine
Phase 2 study evaluating AKS-452 as a Covid-19 booster vaccine was initiated- reported on May 12, 2022.

Phase 2/3 study of AKS-452 was initiated in India-reported on Apr.7, 2022.

Regulatory clearance was received in the Netherlands to conduct Phase 2 study of AKS-452 as a booster dose of Covid-19 vaccine- reported on March 31, 2022.
Submission for Emergency Use Authorization (EUA) is expected by Q3 2022.
-
05/13/2022
SaNOtize Research and Development
Nitric oxide nasal spray
Results from a retrospective study showed that nitric oxide nasal spray is effective in preventing COVID-19 infection after high-risk exposure- reported on May 11, 2022.
-
-
05/12/2022
Vaxart, Inc.
(VXRT)
Oral tablet COVID-19 vaccine
Phase 2 study of Oral Tablet COVID-19 Vaccine was initiated on October 26, 2021.
Data from the dose selection portion of the two part dose-ranging and preliminary efficacy Phase II trials of oral tablet COVID-19 vaccine candidate are expected in the third quarter of 2022.
-
05/11/2022

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...